Search
Scottsdale, AZ Paid Clinical Trials
A listing of 382 clinical trials in Scottsdale, AZ actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
145 - 156 of 382
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 382 clinical trials in Scottsdale, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Arizona, Mayo Clinic, Mayo Clinic Scottsdale and Mayo Clinic Arizona. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Long COVID Cutaneous Signatures: An ARPA Funded Research Project
Recruiting
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/03/2025
Locations: CND Life Sciences, Scottsdale, Arizona
Conditions: Long COVID, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/03/2025
Locations: Retina Macula Institute of Arizona, Scottsdale, Arizona
Conditions: Wet Age Related Macular Degeneration, wAMD
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Recruiting
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona
Conditions: Generalized Myasthenia Gravis
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona
Conditions: Generalized Myasthenia Gravis
PRO1107 in Patients With Advanced Solid Tumors
Recruiting
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Recruiting
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Scottsdale, Arizona
Conditions: Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Assessment of CCM in HF With Higher Ejection Fraction
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: HonorHealth Shea Scottsdale Healthcare, Scottsdale, Arizona
Conditions: Ischemic Stroke, Systemic Embolism
Evolut™ EXPAND TAVR II Pivotal Trial
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/30/2025
Locations: HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona
Conditions: Moderate Aortic Valve Stenosis
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Recruiting
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
* NT1: People with... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/30/2025
Locations: Scottsdale, Arizona, Scottsdale, Arizona
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Recruiting
This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona
Conditions: Advanced/Metastatic Solid Tumors
145 - 156 of 382